Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Meerkuriin pilaanetota biroo jaha kan duraanuu mul'taa jiranitti makamuun pilaanetota torba tarree galanii arguuf jirra jedhu ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Boston, USA-based RNA focused biotech Atalanta Therapeutics today announced the completion of a $97 million Series B ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

Is it cold enough for you? Warm up with the Chagrin Valley Jaycees’ sizzling winter tradition 4-9 p.m. Saturday, Feb. 1 at ...

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...